NCT04114136 2025-02-10
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
16 trialsNCT00004180 2023-06-26
Rosiglitazone in Treating Patients With Liposarcoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01019356 2022-01-20
Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome
Université de Sherbrooke
Phase NA Completed
NCT00616642 2020-08-14
Rosiglitazone in Treating Patients With Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT01287598 2019-07-10
BAY73-4506 Probe Substrate Study
Bayer
Phase 1 Completed
NCT00640224 2017-11-17
Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study
University of Pittsburgh
Phase 4 Completed
NCT03309319 2017-10-13
A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas
Huashan Hospital
Phase NA Unknown
NCT00428090 2017-05-19
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
GlaxoSmithKline
Phase 3 Completed
NCT00933309 2016-02-19
The Impact of Obesity and Obesity Treatments on Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00178841 2016-02-17
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL
Vanderbilt University
Phase 2 Completed
NCT01209143 2015-06-29
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Genentech, Inc.
Phase 1 Completed
NCT00098852 2014-01-06
Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01100619 2013-09-19
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
Exelixis
Phase 1 Completed
NCT00084578 2013-07-15
Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder
Fox Chase Cancer Center
Phase NA Withdrawn
NCT00182052 2013-05-23
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
Massachusetts General Hospital
Phase 3 Completed
NCT00369174 2013-02-13
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia
National Cancer Institute (NCI)
Phase 2 Completed